***Background.*** Heterogeneous vancomycin-intermediate coagulase-negative staphylococci (HCoNS) are emerging pathogens in neonates with central-line associated bloodstream infections (CLABSI). We aimed to compare clinical outcomes of neonates with HCoNS treated with vancomycin vs linezolid.

***Methods.*** Retrospective cohort study of patients with a central line, ≥ 1 positive blood culture for HCoNS and treated with vancomycin or linezolid (2009-2014), from a level III neonatal intensive care unit. Study outcomes were: CLABSI duration, 7-day and 30-day mortality, thrombocytopenia, early CLABSI recurrence (≤ 2 weeks after first negative blood culture) and late recurrence (\> 2 weeks after first negative blood culture). χ^2^ was done for categorical variables and student t-test for continuous variables.

***Results.*** Eighty nine patients were included; 62.9% (n = 56) were treated with vancomycin and 37.1% (n = 33) with linezolid. Vancomycin blood levels were done in 54/56 patients; 70.4% reached therapeutic levels during CLABSI treatment. Of all patients, 51.7% were males and 88.8% born \< 37 weeks. Median gestational age was 27^3/7^ weeks and median birth weight was 805 g. All patients had similar underlying medical diagnoses; 54% with gastrointestinal conditions before CLABSI onset. Risk factors and clinical manifestations of CLABSI did not differ between groups. One third of patients required inotropes for hemodynamic instability and 19% developed necrotizing enterocolitis during or shortly after CLABSI. Median age at CLABSI was 15 days (2-97). *S.epidermidis* was causative in 96.6% of cases. Blood culture became negative within 48h of central line removal in 38% of patients. Statistically significant differences between patients treated with vancomycin vs linezolid included 30-day all-cause mortality (16.1% vs 27.3% respectively, p = 0.019) and late CLABSI recurrence (66.7% vs 0%, p = 0.024). All patients with late recurrences had initially been treated with vancomycin; half had ≥ 2 late recurrences. No significant difference was found for duration of CLABSI, thrombocytopenia, early recurrence, time-to-death or 7-day all-cause mortality.

***Conclusion.*** In our study, vancomycin was as effective as linezolid for treatment of CLABSI caused by HCoNS in neonates. Additionally, we found that linezolid may prevent late CLABSI recurrence.
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